REstoration of Communication and LAnguage With Intracortical Microelectrodes (RECLAIM)
Early Feasibility Study of the Restoration of Communication and Language With Intracortical Microelectrodes (RECLAIM) System
The purpose of this study is to investigate the safety and feasibility of using distributed intracortical recordings from the language network to decode intended language output in individuals with severe communication impairment due to severe communication impairment resulting from amyotrophic lateral sclerosis (ALS), locked-in syndrome, and brain injury including from stroke.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Nitin Tandon, MD
- Telefonnummer: (713) 500-5456
- E-Mail: Nitin.Tandon@uth.tmc.edu
Studieren Sie die Kontaktsicherung
- Name: Eliana Klier, PhD
- Telefonnummer: (713) 500-5442
- E-Mail: Eliana.Klier@uth.tmc.edu
Studienorte
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- The University of Texas Health Science Center at Houston
-
Hauptermittler:
- Nitin Tandon, MD
-
Kontakt:
- Nitin Tandon, MD
- Telefonnummer: (713) 500-5456
- E-Mail: Nitin.Tandon@uth.tmc.edu
-
Kontakt:
- Eliana Klier, PhD
- Telefonnummer: (713) 500-5442
- E-Mail: Eliana.Klier@uth.tmc.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Clinical diagnosis of ALS, locked-in syndrome, or stroke
- ALS - ALS patients who in the opinion of the treating neurologist have at least 3 years of survival
- Locked-in Syndrome as a result of brain-stem stroke or traumatic brain-stem injury - patients who in the opinion of the treating neurologist have at least 3 years of survival
- Stroke (either ischemic or hemorrhagic) - for patients with prior stroke, the original cause of the stroke (e.g., arteriovenous malformation, carotid stenosis, atrial fibrillation, heart disease, hypertension) must have been addressed and the patient must not have had a recurrent stroke at least within the prior 12 months
-
ALS diagnosis, stroke, or Locked-in syndrome (LIS) etiology onset occurred at least one year prior to enrollment
-
Minimal communication ability as assessed by a speech-language pathologist
- unable to produce more than 10 total unique intelligible words when reading the Rainbow Passage and Grandfather Passage, and
- unable to write or type more than 10 unique words from a dictated list of 20 words.
-
Limited upper limb strength based on the Medical Research Council Scale for Muscle Strength
- ≤3/5 strength throughout both arms for those with non-progressive conditions (stroke or traumatic brain-stem injury)
- ≤4/5 strength throughout both arms for those with ALS
i. For patients with 4/5 strength, they must have a documented decline in speech or upper extremity function in the preceding 12 months.
-
Has a means of communication sufficient to enable understanding of research protocol and provide consent (e.g. eye blinks or eye movements, use of assistive technology). Thus patients are severely impaired with regards to naturalistic communication, but able to make decisions regarding their own care
-
Ability to understand and comply with study session instructions
-
Must live within a 90-minute drive of study site and willing to travel to study site up to three days per week for duration of the study
-
Has a stable psychosocial support system with caregiver capable of providing care during post-operative periods and monitoring participant throughout the study
-
Stable ventilator status - ventilator requirements have not changed over prior 6 months and ventilator status does not impose additional substantial risks to subject participation, including travel to the investigation site
Exclusion Criteria:
- Psychiatric conditions including current diagnosis of major psychiatric illness, significant cognitive impairment (based on a neuropsychological assessment by a clinical psychologist), suicidal ideation with intent/plan. [Columbia-Suicide Severity Rating Scale (C-SSRS) Categories 4-5)] or suicidal behavior within 12 months, or substance abuse/narcotic/alcohol dependence within 12 months.
- Neurological disorders including current diagnosis of epilepsy, abnormal pre-surgical neuroimaging precluding safe implant placement (per neurosurgical team), prior ipsilateral craniotomy, or hydrocephalus with or without ventricular shunt.
- Implanted electronic devices including pacemakers, cardiac defibrillators, spinal cord stimulators, vagal nerve stimulators, deep brain stimulators, or cochlear implants.
- Cardiovascular disorders including acute myocardial infarction (MI) or cardiac arrest within 6 months, significant cardiovascular impairment contraindicating surgery.
- Hematological disorders requiring chronic anticoagulation and medical contraindication to discontinuing anticoagulant medications perioperatively.
- Dermatological conditions causing excessive skin sloughing, poor wound healing, existing scalp lesions, or skin breakdown.
- Infectious/immunological conditions including active infections, unexplained fever, HIV infection, ongoing chronic infections, medical conditions predisposing to high infection risk, chronic steroid or immunosuppressive therapy, or active cancer within 1 year requiring chemotherapy.
- Medical contraindications including conditions contraindicating chronically implanted devices (osteomyelitis, diabetes, hepatic failure, autoimmune disease/disorders with associated altered immune responses) or other chronic unstable medical conditions interfering with participation.
- Surgical contraindications including medical contraindications to general anesthesia, craniotomy, or surgery; significant pulmonary, metabolic, or renal impairments making surgical procedure unsafe.
- Other exclusions including pregnancy (confirmed by blood test), nursing, inadequate contraception, correction vision worse than 20/100, limited English proficiency, or concurrent participation in device/drug trials.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: RECLAIM System
|
6 microelectrode grids will be implanted within the dominant hemisphere, placed across key speech and language cortical regions. The device will be kept implanted for up to 5 years and study sessions will be conducted 3-5 times per week |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Safety as assessed by the number and type of adverse events that occur
Zeitfenster: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety as assessed by the number of participants with device explanted
Zeitfenster: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
|
|
Safety as assessed by the number of participants with Serious Adverse Events that result in death or permanently increased disability
Zeitfenster: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
|
|
Effectiveness of the device as assessed by the Word error rate (WER)
Zeitfenster: Every three months for the first two years post-implant
|
Every three months for the first two years post-implant
|
|
|
Effectiveness of device as assessed by the Phoneme error rate (PER)
Zeitfenster: Every three months for the first two years post-implant
|
Every three months for the first two years post-implant
|
|
|
Effectiveness of the device as assessed by the Bilingual Evaluation Understudy (BLEU) Score
Zeitfenster: Every three months for the first two years post-implant
|
BLEU (Bilingual Evaluation Understudy) quantifies, on a range of 0-1, the overlap between the decoded text and the reference text based on matching n-grams. Higher BLEU scores indicate that the decoded output more closely matches the reference at the level of local word sequences. |
Every three months for the first two years post-implant
|
|
Effectiveness of the device as assessed by the Bidirectional Encoder Representations from Transformers (BERT) Score
Zeitfenster: Every three months for the first two years post-implant
|
BERT Score compares the semantic similarity (on a range of -1 to 1) between the decoded text sequence and the reference text using a pretrained language model (BERT). Higher scores indicated stronger semantic alignment. |
Every three months for the first two years post-implant
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Psychische Störungen
- Wunden und Verletzungen
- Neuromuskuläre Erkrankungen
- Stoffwechselerkrankungen
- Neurobehaviorale Manifestationen
- Neurodegenerative Krankheiten
- Neuroentwicklungsstörungen
- Kraniozerebrales Trauma
- Trauma, Nervensystem
- Erkrankungen des Rückenmarks
- TDP-43 Proteinopathien
- Proteostase-Mängel
- Motoneuron-Krankheit
- Lähmung
- Tetraplegie
- Pathologische Zustände, Anzeichen und Symptome
- Ernährungs- und Stoffwechselerkrankungen
- Anzeichen und Symptome
- Locked-In-Syndrom
- Streicheln
- Hirnverletzungen
- Amyotrophe Lateralsklerose
- Kommunikationsstörungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- HSC-MS-26-0020
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .